These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 21680863)

  • 1. HTS promiscuity analyses for accelerating decision making.
    Böcker A; Bonneau PR; Edwards PJ
    J Biomol Screen; 2011 Aug; 16(7):765-74. PubMed ID: 21680863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of mixture distributions to deconvolute the behavior of "hits" and controls in high-throughput screening data.
    Buxser S; Chapman DL
    Anal Biochem; 2007 Feb; 361(2):197-209. PubMed ID: 17214952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistics and decision making in high-throughput screening.
    Coma I; Herranz J; Martin J
    Methods Mol Biol; 2009; 565():69-106. PubMed ID: 19551358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the biological promiscuity of high-throughput screening hits through DFT calculations.
    Curpăn R; Avram S; Vianello R; Bologa C
    Bioorg Med Chem; 2014 Apr; 22(8):2461-8. PubMed ID: 24656802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel trends in high-throughput screening.
    Mayr LM; Bojanic D
    Curr Opin Pharmacol; 2009 Oct; 9(5):580-8. PubMed ID: 19775937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virtual screening to enrich hit lists from high-throughput screening: a case study on small-molecule inhibitors of angiogenin.
    Jenkins JL; Kao RY; Shapiro R
    Proteins; 2003 Jan; 50(1):81-93. PubMed ID: 12471601
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying actives from HTS data sets: practical approaches for the selection of an appropriate HTS data-processing method and quality control review.
    Shun TY; Lazo JS; Sharlow ER; Johnston PA
    J Biomol Screen; 2011 Jan; 16(1):1-14. PubMed ID: 21160066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medicinal chemistry tools: making sense of HTS data.
    Kolossov E; Lemon A
    Eur J Med Chem; 2006 Feb; 41(2):166-75. PubMed ID: 16368163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multidimensional profiling of CSF1R screening hits and inhibitors: assessing cellular activity, target residence time, and selectivity in a higher throughput way.
    Uitdehaag JC; Sünnen CM; van Doornmalen AM; de Rouw N; Oubrie A; Azevedo R; Ziebell M; Nickbarg E; Karstens WJ; Ruygrok S
    J Biomol Screen; 2011 Oct; 16(9):1007-17. PubMed ID: 21873591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Which aspects of HTS are empirically correlated with downstream success?
    Bender A; Bojanic D; Davies JW; Crisman TJ; Mikhailov D; Scheiber J; Jenkins JL; Deng Z; Hill WA; Popov M; Jacoby E; Glick M
    Curr Opin Drug Discov Devel; 2008 May; 11(3):327-37. PubMed ID: 18428086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel statistical approach for primary high-throughput screening hit selection.
    Yan SF; Asatryan H; Li J; Zhou Y
    J Chem Inf Model; 2005; 45(6):1784-90. PubMed ID: 16309285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced HTS hit selection via a local hit rate analysis.
    Posner BA; Xi H; Mills JE
    J Chem Inf Model; 2009 Oct; 49(10):2202-10. PubMed ID: 19795815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantification of frequent-hitter behavior based on historical high-throughput screening data.
    M Nissink JW; Blackburn S
    Future Med Chem; 2014 Jun; 6(10):1113-26. PubMed ID: 25078133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian versus Frequentist statistical modeling: a debate for hit selection from HTS campaigns.
    Cloutier LM; Sirois S
    Drug Discov Today; 2008 Jun; 13(11-12):536-42. PubMed ID: 18549981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-throughput assays for promiscuous inhibitors.
    Feng BY; Shelat A; Doman TN; Guy RK; Shoichet BK
    Nat Chem Biol; 2005 Aug; 1(3):146-8. PubMed ID: 16408018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypothesis testing in high-throughput screening for drug discovery.
    Prummer M
    J Biomol Screen; 2012 Apr; 17(4):519-29. PubMed ID: 22233646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.
    Baell JB; Holloway GA
    J Med Chem; 2010 Apr; 53(7):2719-40. PubMed ID: 20131845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using clustering techniques to improve hit selection in high-throughput screening.
    Gagarin A; Makarenkov V; Zentilli P
    J Biomol Screen; 2006 Dec; 11(8):903-14. PubMed ID: 17092911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trends in kinase selectivity: insights for target class-focused library screening.
    Posy SL; Hermsmeier MA; Vaccaro W; Ott KH; Todderud G; Lippy JS; Trainor GL; Loughney DA; Johnson SR
    J Med Chem; 2011 Jan; 54(1):54-66. PubMed ID: 21128601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-throughput biochemical kinase selectivity assays: panel development and screening applications.
    Card A; Caldwell C; Min H; Lokchander B; Hualin Xi ; Sciabola S; Kamath AV; Clugston SL; Tschantz WR; Leyu Wang ; Moshinsky DJ
    J Biomol Screen; 2009 Jan; 14(1):31-42. PubMed ID: 19073965
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.